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Abstract
Background: Female CD-1/Swiss Webster mice subjected to incessant ovulation for 8 months and 12-
month breeder mice both developed ovarian inclusion cysts similar to serous cystadenomas. The majority
of cysts appeared to be dilated rete ovarii tubules, but high ovulation number resulted in more cortical
inclusion cysts. We hypothesized that comparison of inclusion cyst pathology in animals of the same age,
but with differences in total lifetime ovulation number, might allow us to determine distinguishing
characteristics of the two types of cyst.
Methods: Ovaries from breeder mice (BR) or females subjected to incessant ovulation (IO) were
compared at 6-, 9- and 12-months of age. Ovaries were serially sectioned and cysts characterized with
regard to location and histology, E-cadherin immunoreactivity and rates of BrdU incorporation.
Results: Inclusion cysts developed with age in BR and IO ovaries. The majority of cysts were connected
to the ovarian hilus. Two cortical inclusion cysts were observed in ten IO ovaries and one in ten BR
ovaries. Low or no E-cadherin immuno-staining was seen in the OSE of all mice studied. Conversely, strong
membrane immuno-staining was observed in rete ovarii epithelial cells. Variable E-cadherin
immunoreactivity was seen in cells of hilar inclusion cysts, with strong staining observed in cuboidal ciliated
cells and little or no staining in flat epithelial cells. Two of the three cortical cysts contained papillae, which
showed E-cadherin immuno-staining at the edge of cells. However hilar and cortical cysts were not
distinguishable by morphology, cell type or E-cadherin immunoreactivity. BrdU incorporation in cyst cells
(1.4% [95% CI: 1.0 to 2.1]) was greater than in OSE (0.7% [95% CI: 0.4 to 1.2]) and very few BrdU-labeled
cells were observed in rete ovarii at any age. Incessant ovulation significantly increased BrdU incorporation
in OSE of older animals.
Conclusion: These experiments confirm ovarian inclusion cysts develop with age in the CD-1 mouse
strain, irrespective of total ovulation burden. We conclude longer periods of incessant ovulation do not
lead to significant changes in inclusion cyst formation or steroidogenesis in CD-1 mice and inclusion cyst
type can not be distinguished by morphology, cell proliferation rate or E-cadherin immunoreactivity.
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Background
Our previous studies demonstrated that ovaries of CD-1/
Swiss Webster mice subjected to incessant ovulation (IO)
had changes suggestive of a precancerous state, such as an
increased number of surface invaginations, stratification
of the ovarian surface epithelium (OSE) and inclusion
cyst formation [1,2]. Dilation of the rete ovarii tubules to
form serous inclusion cysts also occurred with age in
breeding females with a much lower total ovulation
number [2]. However these studies compared ovaries
from incessantly ovulated ovaries and breeders of differ-
ent ages. We hypothesized that comparison of inclusion
cyst pathology in animals of the same age, but with large
differences in total lifetime ovulation number, might
allow us to distinguish better between cortical and rete
ovarii cysts. We have therefore compared age-matched
mice subjected to incessant ovulation or repeated preg-
nancy for up to 12 months and assessed ovarian histol-
ogy, rates of cell division and expression of the epithelial
marker E-cadherin.
E-cadherin is a regulator of the differentiated epithelial
cell phenotype, with key roles in the formation of cell
adherens junctions and the establishment of epithelial
polarity [3]. Mutation or abnormal expression of E-cad-
herin is known to be carcinogenic in a variety of epithelial
tissues [4-6]. The OSE is continuous with the mesothe-
lium covering the peritoneal cavity and is therefore better
classified as a mesothelium, rather than a true epithelium
[7]. Normal OSE and peritoneal mesothelial cells express
little to no E-cadherin [8,9], but transformed OSE cells
and cells from primary epithelial ovarian cancer (EOC)
have increased E-cadherin expression [9-12]. Expression
of exogenous E-cadherin in OSE cells can induce a mesen-
chymal-to-epithelial transition in the OSE, resulting in the
expression of cytokeratins and a cobblestone epithelial
appearance in culture [11]. Loss of E-cadherin expression
predicts poor prognosis, especially in late-stage, serous
EOC [3]. E-cadherin protein has been reported to be
absent from the cells of the human rete ovarii [13],
although it appears to be present in the mesonephros and
mesonephric tubules of the fetal mouse ovary [14], from
which the adult rete ovarii are derived. We therefore meas-
ured E-cadherin expression in our model of incessant ovu-
lation, to compare expression in the cells lining inclusion
cysts with that in the OSE or rete ovarii.
Methods
Animals
Experiments were approved by the University of Otago
Animal Ethics Committee. The dissection, fixation, and
processing of the ovaries has been described previously, as
has estimation of total lifetime ovulation number [1,2].
Female out-bred CD-1/Swiss Webster mice were housed
in two groups in a temperature- and light-controlled facil-
ity; (1) in breeding pairs (BR group) with one female
housed with a male Swiss Webster mouse and (2) in a
cage divided by a perforated screen, with two females
housed beside, but not in contact with a single male
mouse, to induce incessant ovulation (IO group) and pre-
vent breeding [1]. Breeder females were separated from
their males at the appropriate age, on weaning of the last
litter. Mice were housed in these environments from age
of weaning until 6, 9 or 12-months of age. Blood samples
were obtained on euthanasia from all mice and cyst fluid
was aspirated on ovarian dissection where possible.
Determination of stage of estrous cycle
Vaginal cytology was monitored in BR and IO mice using
the lavage method [15] to check the mice were cycling reg-
ularly. Vaginal smears were taken in the morning before
1000 hours for no more than five consecutive days. Once
they had reached the appropriate age, vaginal smears were
taken to determine stage of cycle and the animals were
killed at between 1300 and 1500 hours on the afternoon
of the 0600 hours estrus smear.
Plasma collection
Mice were anesthetized with halothane gas and cardiac
puncture exsanguination was performed using a 26 gauge
needle and a heparinized syringe. One to 2 ml of blood
was obtained from each animal and the plasma was
stored at -80°C until assay.
Cyst fluid collection
Fluid was aspirated from ovaries containing visible cysts,
using an ultra-fine insulin needle and 1.0 ml syringe.
Fluid was frozen at -80°C before use and diluted 1/20
before estradiol-17β radioimmunoassay. Between 20 and
950 μl cyst fluid was obtained from nine ovaries. Cyst
fluid was assayed for estradiol-17β only.
Determination of inclusion cysts and dilated rete ovarii
One ovary from 10 mice from the IO and BR treatment
groups at each age was removed at time of death and fixed
in 4% paraformaldehyde for 18 hours, before embedding
in paraffin and serial sectioning at a 4 μm thickness. Every
25th  section was stained with hematoxylin and eosin
(H&E) and the number of cystic structures and/or dilated
rete ovarii determined [2].
BrdU incorporation
Mice were injected three times i.p. with 3 mg/100 g body
weight of BrdU, dissolved in sterile isotonic saline, at
0700 h, 0900 h and 1100 h, before euthanasia at 1300 h.
The harvested ovaries were fixed in 4% paraformalde-
hyde, embedded in paraffin and BrdU immunohisto-
chemistry was performed on 4 μm sections adjacent to the
H&E stained sections containing cysts or rete ovarii from
each animal. Antigenic sites were exposed by incubationReproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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with 5 μg/ml proteinase K (Sigma-Aldrich Inc., St Louis,
MO USA)for 25 min at 37°C and DNA denatured by incu-
bation in 4 M HCl for 10 min at room temperature. The
acid was neutralized by washing in 0.1 M sodium borate
for 10 min at room temperature and endogenous peroxi-
dase quenched by incubation with 0.3 % (v/v) H2O2 in
methanol. Sections were incubated with 50 μl/section
1:50 dilution of a monoclonal mouse anti-BrdU antibody
(Dako, Carpentaria, USA) in phosphate buffered saline
containing 1% bovine serum albumin (PBS-BSA; Sigma-
Aldrich) overnight at 4°C. Negative control slides were
incubated in PBS-BSA without primary antibody. Sections
were incubated with a 1:200 dilution of biotin-conjugated
goat anti-mouse IgG (Amersham GE Healthcare UK Ltd,
Buckinghamshire HP7 9NA, England), before incubation
with streptavidin biotinylated horseradish peroxidase
(Amersham) for one hour at room temperature. Labeled
cells were visualized with diaminobenzidine (DAB; Vector
Laboratories Inc., Peterborough, UK). All OSE, rete ovarii
and cyst epithelial cells in each stained section were
scored for nuclear BrdU staining and % incorporation cal-
culated as the number of stained cells as a percentage of
the total number of cells counted for each cell type. All
ovaries were collected on the afternoon of estrus and thus
all ovaries contained ovulation sites, but not all sections
analyzed for BrdU incorporation contained obvious ovu-
lation sites.
E-cadherin immunohistochemistry
E-cadherin immunohistochemistry was performed after
antigen retrieval by microwaving in boiling 1 mM EDTA,
pH 8.0, using a rat anti-mouse E-cadherin monoclonal
primary antibody (Clone ECCD-2, Isotype Rat IgG2a,
Zymed Laboratories, San Francisco, CA, USA; 100 μg/ml),
incubated overnight at 4°C. Sections were then incubated
with a goat anti-rat biotinylated secondary antibody
(1:100 dilution; Zymed), before incubation with strepta-
vidin biotinylated horseradish peroxidase (1:50 dilution;
Amersham) for one hour at room temperature. Labeled
cells were visualized with DAB and sections counter-
stained with 50% Gill's hematoxylin.
E-cadherin immunoblotting
Samples of mouse whole ovary, uterus, small intestine
(positive controls) and skeletal muscle (negative control)
were snap frozen, pulverized in liquid nitrogen and the
protein extracted in SDS reducing buffer as previously
described [16]. Protein concentrations were determined
using a bicinchoninic acid protein assay kit (Pierce Bio-
technology, Rockford, IL). Protein extracts were separated
on discontinuous 8% SDS-PAGE gels and electroblotted
onto polyvinylidene difluoride membranes (PVDF, Roche
Pharmaceuticals, Auckland, New Zealand). A 10–250 kDa
pre-stained protein marker was loaded onto all gels. Blots
were probed for 1 h at room temperature with the E-cad-
herin primary antibody (Zymed Clone ECCD-2; 1 μg/ml)
in phosphate buffered saline, pH 7.4, containing 0.1% (v/
v) Tween 20 and 3% (w/v) skim milk powder (PBS-TM).
Membranes were washed and incubated with horserad-
ish-peroxidase-conjugated goat anti-rat immunoglobu-
lins (Zymed; diluted 1:2000 in PBS-TM) for 1 h at room
temperature, followed by incubation with streptavidin
biotinylated horseradish peroxidase (Amersham) at a
dilution of 1:5000 in TBS for 1 hour, prior to detection of
bound antibody with the ECL chemiluminescent detec-
tion system (Amersham) according to the manufacturer's
directions [17].
Plasma steroid radioimmunoassay
Radioimmunoassay (RIA) kits were obtained from Diag-
nostic Systems Laboratories (DSL, Webster, Texas, USA) to
measure the concentration of estradiol-17β (DSL-39100
3rd generation 17β-Estradiol RIA Kit), total testosterone
(DSL-4000 ACTIVE® Testosterone Coated-Tube Radioim-
munoassay Kit), and androstenedione (DSL-3800
ACTIVE®  Androstenedione Coated Tube Radioimmu-
noassay Kit). Each RIA was performed according to the
manufacturer's instructions and all plasma samples were
assayed in duplicate. Five separate assays containing sam-
ples from a random selection of treatment groups were
carried out. Plasma samples were diluted in assay buffer
containing 0.1% (w/v) bovine serum albumin (BSA).
Dilution factors ranged between 1 and 10, depending on
the amount of plasma available for each sample. Three
independent assays were carried out for testosterone and
androstenedione measurements, none of which required
sample dilution. RIA data were analyzed using a universal
assay calculator computer software package (BIOSOFT
AssayZap V 2.51, 1995). The sample intra-assay coeffi-
cient of variation (CV) ranged from 8.6% to 12.9% for the
estradiol-17β assays, 17.8% to 18.6% for testosterone and
7.5% to 16.2% for the androstenedione assays. Inter-assay
CVs were determined using results for high and low qual-
ity control (QC) samples across all assays. Inter-assay CV
for estradiol-17β: low QC (10 pg/ml) = 17.0%, high QC
(30 pg/ml) = 6.5%; testosterone: low QC (0.5 ng/ml) =
19.7%, high QC (5.0 ng/ml) = 5.2%; androstenedione:
low QC (0.9 ng/ml) = 13.3%, high QC (6.0 ng/ml) =
15.0%.
Data Analysis
All statistical analyses were conducted using SPSS 14.0
(SPSS, Chicago, USA) or SAS 9.1.2 (SAS Institute Inc.,
Cary, NC, USA). A P-value < 0.05 was considered to be sta-
tistically significant.
BrdU incorporations analysis
Group mean BrdU incorporations were compared using
negative binomial regression. Age group, treatment group
and the interaction of age and treatment groups wereReproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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included as explanatory variables in the model. Pairwise
comparisons with a Bonferroni correction were per-
formed to determine which groups were significantly dif-
ferent if differences were found in the regression analysis.
Analyses were performed for OSE and cyst cells separately.
Negative binomial regression using generalized estimat-
ing equations was used to compare the OSE BrdU incor-
poration rate with the cyst cell incorporation rate in those
animals that had cysts. The generalized estimating equa-
tion accounts for correlation among observations from
the same animal.
Steroid data analysis
For all analyses, testosterone and androstenedione
plasma concentrations were log transformed before anal-
ysis, because of their positively skewed distributions. The
original data for estradiol were used in the analysis. Group
mean values in steroid data were compared using a 2-way
ANOVA grouped on age (6, 9 12-months) and treatment
(BR, IO). The main effects and the interaction were
included in the model. Pairwise comparisons with a Bon-
ferroni correction were performed to determine which
groups were significantly different, if differences were
found with the 2-way ANOVA. A linear mixed model was
used to compare the mean estradiol in plasma with the
mean estradiol in cyst fluid for animals that had a cyst.
The fixed effect was section (plasma, cyst) and the random
effect was the animal. The random animal effect allows us
to model possible correlations between measurements
from the same animal. Plasma steroid levels were initially
compared in animals with ovarian inclusion cysts or
dilated rete ovarii and those without using an independ-
ent samples t-test. To adjust for the potential confounding
effect of age group, a linear regression analysis was also
performed with cyst presence and age group as explana-
tory variables in the model.
Results
Estimated ovulation numbers
Total lifetime ovulation number was estimated from the
records of the breeding pairs, as described previously
[1,2]. Although litter size declined only minimally
between 6 and 12-months of age, a decrease in litter fre-
quency led to a significant decline in the number of pups
born per month to the breeding pairs. The mean esti-
mated total ovulation number for each treatment group
and age is shown in Table 1. These values are estimated
from average litter size over lifetime, as well as minimum
and maximum age of puberty and estrous cycle length and
are therefore under-estimations of true ovulation burden
[1]. Body weight increased with age in IO mice, but not
from 6 months of age in BR mice (Table 1).
Frequency of ovarian inclusion cysts and dilated rete ovarii
Ovarian cysts were common across all age and ovulation
groups on inspection of histological sections (Table 2).
Cyst size and cellular metaplasia increased with age (Fig-
ure 1). Serial ovarian sectioning showed the majority of
cysts were hilar in origin and appeared to be dilated rete
ovarii, but in one case the cyst was so large its origin could
not be determined. True cortical inclusion cysts, with no
connection to the ovarian hilus, were rare in both groups.
Of the four cortical inclusion cysts observed on serial sec-
tioning, three were in 6-, 9- and 12-month IO ovaries and
one was in a 9-month old BR ovary (Figure 1 and Table 2).
This breeder had had eight litters and a total of 114 pups
in her lifetime, with an estimated ovulation number of
182–250, similar to the other animals in her group.
Cyst cell morphology
Most cysts were typically lined with a single layer of epi-
thelial cells, ranging in shape from flat to cuboidal or
columnar, with cilia frequently present on the cuboidal
and columnar cells. Two of the three cortical inclusion
cysts were lined only with cuboidal and columnar cells,
with a noticeable absence of any flat cells. Many of the
columnar cells had nuclei with an apical location and no
cilia were seen on these cells. Papillae were observed in
both dilated rete ovarii and cortical inclusion cysts with
no apparent connection to the hilus. Cortical cysts were
distinguished from cystic follicles by lack of a thecal layer
Table 1: Numbers (n) of mice, age in days (sd), mean body weight in grams (sd) and estimated mean total lifetime ovulation number 
(OV#: minimum – maximum estimate) in mice subjected to incessant ovulation (IO) or repeated pregnancy (BR) from 6–12 months 
(m) of age.
Group Treatment Age (days) n Body weight (g) Estimated OV# (min – max)
6 m IO 193 (3) 10 43 (3) 336 (284–388)
BR 190 (6) 17 45 (3) 161 (129–193)
9 m IO 275 (12) 14 50 (2) 642 (585–698)
BR 300 (3) 19 42 (3) 188 (155–222)
12 m IO 374 (1) 18 53 (2) 720 (561–878)
BR 392 (9) 16 45 (4) 286 (206–367)
OV# was estimated as described previously [1].Reproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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beneath the cyst epithelium and by the presence of flat-
tened or ciliated cells.
E-cadherin immunoblotting and immunohistochemistry
No or extremely low levels of E-cadherin immunoreactiv-
ity were observed in the ovaries of BR or IO ovaries at any
age, using the immunohistochemical conditions
employed in this study. In particular, the OSE was essen-
tially negative for E-cadherin immunostaining. Invagina-
tions of the OSE did not show increased E-cadherin
immunoreactivity (data not shown), but some staining
was observed occasionally in the OSE close to the OSE-
mesothelial junction (Figure 2A and 2B). In contrast,
strong immunoreactivity was observed on the edges of
both intra- and extra-ovarian rete ovarii tubule cells (Fig-
ure 2C and 2D). In large hilar cysts, E-cadherin immuno-
reactivity was more variable and flat cells had no
membrane-limited staining, whereas staining around cili-
ated and cuboidal cells remained strong (Figure 2E and
2G). One cortical inclusion cyst had little E-cadherin
immunoreactivity (Figure 2F), whereas the two with
extensive papillae formation showed strong membrane
staining (Figure 2H).
Immunoreactive bands of around 120 kDa and 75 KDa
[10,18] were seen on immunoblotting of 5 or 20 μg pro-
tein extracted from uterus or small intestine, but no or
very low signals were observed in extracts of whole ovary
or skeletal muscle. An immunoreactive band was also
seen at 60 KDa, particularly in uterine and ovarian extracts
(Figure 3). Non-specific immunoreactivity migrated at the
gel front in all lanes with 20 μg protein extract (data not
shown).
BrdU incorporation
BrdU immunohistochemically-stained nuclei were
observed in sections of all ovaries, regardless of age or
ovulation number. Within the ovaries, numerous granu-
losa and theca cells in the developing follicles showed
BrdU incorporation, with stained nuclei also evident in
the corpora lutea and stroma (Figure 4).
The percentages of BrdU-stained nuclei in OSE, cyst epi-
thelia or rete ovarii tubules are shown in Table 3. Num-
bers of BrdU-stained nuclei in ovarian epithelial cells were
low and the highest rates of incorporation were observed
in the cyst epithelium, at levels of around 1–2% (Table 3).
BrdU incorporation was evident in < 1% of OSE nuclei,
although numbers varied greatly between animals of the
same age and stage of estrous cycle. Figure 4 shows repre-
sentative examples of BrdU immunohistochemistry in the
OSE, rete ovarii and epithelial cells lining cysts. OSE cell
labeling was most frequently seen at the base of fresh ovu-
lation sites. Labeled cuboidal cells also appeared at ran-
dom throughout the OSE. No increase in BrdU
incorporation was noted in the region of the transition
between the OSE and the peritoneal mesothelium, at the
hilus of the ovary (data not shown).
BrdU incorporation rate was examined in ovarian cyst epi-
thelia from 36 animals. Data for each age and treatment
group combination are described in Table 3. Neither the
main effects of age (P = 0.500) nor treatment group (P =
0.761) nor the interaction term (P = 0.721) were statisti-
cally significant for cyst cells, suggesting BrdU incorpora-
tion did not decline significantly with age in cyst cells.
BrdU incorporation in the OSE was compared with that in
cyst epithelium of the same ovary in the 36 animals that
had cysts. There was a statistically significant difference in
BrdU incorporation rate in OSE compared with cyst cells
(P = 0.011). The predicted percentage proliferation rate in
OSE was 0.7% (95% CI: 0.4 to 1.2) and in cysts was 1.4%
(1.0 to 2.1). The average BrdU incorporation rate for the
OSE was 0.50 times that of the cysts (95% CI: 0.30 to
0.85).
Data on BrdU incorporation rate in the normal rete ovarii
tubules were available for 16 animals. Stained nuclei were
Table 2: Numbers of cysts in ovaries of mice subjected to incessant ovulation (IO) or repeated pregnancy (BR) from weaning until 6–12 
months of age. Ten ovaries from each group were serially sectioned to determine the extent and origin of the cysts and rete ovarii 
tubules (RO). The number of ovaries containing cysts of different types is given. Ovaries could contain more than one type of cyst. In 
one case the cyst was so large that, after aspiration of cyst fluid on dissection, the origin of the cyst could not be determined. There 
were no differences in the frequency of cortical cysts between groups.
Age 6-month 9-month 12-month
Group IO BR IO BR IO BR
Number of ovaries examined 10 10 10 10 10 10
Ovaries containing cysts 6 6 8 8 7 8
Ovaries with extra-ovarian cysts 1 2 2 2 0 5
Ovaries with hilar inclusion cysts 5 5 6 6 6 5
Ovaries with cortical inclusion cysts 0 0 1 1 1 0
Ovaries with cysts of unknown origin 0 0 1 0 0 0Reproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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only observed in five (31%) of the rete ovarii samples
observed. The median (IQR) percentage BrdU incorpora-
tion rate was 0.0 (0.0, 0.5). As the proliferation rates were
so low, differences between age groups or treatment
groups were not tested.
Incessant ovulation increased BrdU incorporation in the 
OSE
Data on BrdU incorporation in OSE were available for 59
animals and are shown in Figure 5. BrdU incorporation
declined with age in the OSE. The main effects of age and
Cyst size and cellular metaplasia increased with age in both BR (A-C) and IO (D-F) mice Figure 1
Cyst size and cellular metaplasia increased with age in both BR (A-C) and IO (D-F) mice. A. Intraovarian cyst (c) in an ovary 
from a 6-month BR mouse. Serial sectioning of this ovary showed this cyst originated in the hilus of the ovary. Dilated rete 
ovarii tubules (RO) are present in the extra-ovarian fat. B. Ovary from a 9-month BR mouse, containing an intraovarian corti-
cal cyst with many papillae (right) and a hilar cyst (lower left). C. Ovary from a 12-month BR mouse containing a large, col-
lapsed hilar cyst, from which cyst fluid has been aspirated. D. Cyst in the medulla of a 6-month IO mouse, which was shown to 
be connected to the hilus of the ovary on serial sectioning. E. Collapsed cyst of unknown origin in the ovary of a 9-month IO 
mouse. The original diameter of this ovary was 11 mm before aspiration of 950 μl of cyst fluid. F. Hilar cyst with extensive 
papillae formation in an ovary from a 12-month IO mouse.
C B
c
c
9 m BR 12 m BR
D
c
6 m IO
E
c
9 m IO
F
c
12 m IO
A
c
6 m BR
RO
G
c
Table 3: Median (IQR) percentages of BrdU-stained nuclei observed in the OSE and cyst epithelia and median (range) of BrdU-stained 
nuclei observed in normal rete ovarii of mice of different ages and total lifetime ovulation number.
Group Treatment OSE n = 59 Cyst n = 36 Rete ovarii n = 16 Median(range)
6 m IO 1.3 (0.0, 2.6) 2.2 (0.0, 2.8) 0.0 (0.0, 2.0)
BR 0.4 (0.1, 3.3) 0.9 (0.6, 4.0) 0.0 (0.0, 0.0)
9 m IO 0.7 (0.2, 1.3) 0.5 (0.1, 3.2) 0.0 (-) *
BR 0.1 (0.0, 0.2) 1.5 (0.8, 2.3) 0.3 (0.0, 0.7)
12 m IO 0.2 (0.0, 0.7) 0.0 (0.0, 1.9) - **
BR 0.1 (0.0, 0.1) 0.3 (0.0, 1.9) 0.0 (0.0, 2.0)
* Normal rete ovarii tubules were observed in only one animal in this group.
** No normal, undilated rete ovarii tubules were observed in ovaries from this group.Reproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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E-cadherin immunoreactivity in the epithelial cells of cystic mouse ovaries Figure 2
E-cadherin immunoreactivity in the epithelial cells of cystic mouse ovaries. A. OSE to mesothelial junction of an ovary from a 
6-month BR mouse; negative control without primary antibody. B. A small amount of E-cadherin immunoreactivity can be seen 
in the OSE, but not the mesothelium of a serial section to A. C. Strong junctional E-cadherin immuno-staining in extra-ovarian 
rete ovarii from a 6-month IO mouse. D. E-cadherin immuno-staining in an intra-ovarian rete ovarii tubule from a 6-month IO 
mouse. E. Ciliated cells lining a hilar ovarian inclusion cyst show E-cadherin immunoreactivity, whereas flatter cells lining the 
cyst are unstained. F. Cells lining a cortical inclusion cyst from a 9-month IO ovary showing very little membrane-bound E-cad-
herin immuno-staining. Insert shows the negative control without primary antibody. G. Lack of E-cadherin junctional immuno-
staining in some, but not all cells lining an inclusion cyst connected to the ovarian hilus, in a 6-month IO ovary. H. Strong mem-
brane-limited E-cadherin immunoreactivity in cells of papillae in a cortical inclusion cyst from a 12-month IO ovary.
25 μm
100 μm
A B
CD
G
25 μm
100 μm
E
H
100 μm
F
100 μm
100 μm
100 μm 100 μm
100 μm
20 μm
-veReproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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treatment were statistically significant (P < 0.001 and P =
0.002 respectively), but the interaction was not (P =
0.089). The BrdU incorporation rate in the IO group was
3.1 times (95% CI: 1.5 to 6.4) the BrdU incorporation in
the BR group. The BrdU incorporation rate was signifi-
cantly higher for the 6-month compared to the 9-month
(incidence rate ratio = 3.7, 95% CI: 1.6 to 8.2, P = 0.002)
and 12-month mice (incidence rate ratio = 7.9, 95% CI:
3.3 to 19.0, P < 0.001). There was a tendency towards
BrdU incorporation being higher in the 9-month com-
pared with the 12-month mice, but this was not statisti-
cally significant (incidence rate ratio = 2.2, 95% CI: 0.9 to
5.3, P = 0.098).
Rates of apoptosis
Very few apoptotic epithelial cells were detected in OSE,
cysts or rete ovarii using either active caspase-3 immuno-
histochemistry or TUNEL in situ hybridization (data not
shown), despite numerous positive cells in atretic folli-
cles. In the 100 ovarian sections analyzed, a total of five
OSE cells and four cyst cells labeled positive for the active
caspase-3 protein. These were observed in ovaries from all
ages and treatment groups. In all ovarian sections ana-
lyzed, no rete ovarii cells labeled positive for the active
caspase-3 protein and two positive cells were seen after
TUNEL labeling.
Plasma steroid concentrations across ages and ovulation 
groups
The plasma steroid concentrations for each age and ovula-
tion group combination are described in Table 4. Estra-
diol-17β concentrations are described by the mean and
standard deviation and those of testosterone and andros-
tenedione are described by the median and inter-quartile
range (IQR). Separate 2-way ANOVAs for each of the
plasma steroid concentrations showed there was no inter-
action effect, i.e. the effect of treatment did not differ by
age. The P-values for estradiol, testosterone and andros-
tenedione were 0.462, 0.619 and 0.718, respectively.
There was also no treatment effect (P = 0.984, 0.915 and
0.284). There was a significant decline with age in testo-
sterone (P = 0.001) and androstenedione (P < 0.001) con-
centrations, but there were no significant differences in
circulating estradiol-17β between age groups (P = 0.178).
For testosterone, the geometric mean was significantly
higher for the 6-month compared with the 9-month (P =
0.002) and 12-month mice (P = 0.003). Likewise for
androstenedione, the geometric mean was significantly
higher for the 6-month mice compared with 9-month (P
= 0.009) and 12-month mice (P < 0.001).
Does the level of estradiol-17β in cyst fluid differ from that 
in plasma from the same animal?
Gross examination of the ovaries on dissection revealed
protruding fluid-filled cysts of >2 mm diameter in some
older IO and BR animals. An adequate amount of cyst
fluid was extracted for estradiol-17β RIA analysis in nine
of these cysts and compared with plasma estradiol-17β
levels in the same animal to investigate any possible dif-
ferences in steroid concentrations between these two
sources. Data on plasma estradiol was available for 7 of
the 9 animals with cysts. The linear mixed model found
E-cadherin immunoblot of 5 μg and 20 μg extracted protein from whole mouse ovary (Ov), uterus (U), small intestine (SI) and  skeletal muscle (M) Figure 3
E-cadherin immunoblot of 5 μg and 20 μg extracted protein from whole mouse ovary (Ov), uterus (U), small intestine (SI) and 
skeletal muscle (M).
120 KDa
Ov U SI M Ov U         SI        M
20 μg                                5 μg
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no statistically significant differences in mean estradiol-
17β levels between the cyst fluid and the plasma (P =
0.102). The mean plasma estradiol-17β in the nine ani-
mals where cyst fluid was obtained was 29.5 pg/ml (95%
CI: 12.3 to 46.6), whereas the mean estradiol-17β in cyst
fluid was 44.9 pg/ml (95% CI: 29.3 to 60.5). Although
not statistically significant, there was a tendency for the
estradiol concentration to be higher in the cyst fluid than
in the plasma (difference in means = 15.42, 95% CI: [-
3.85 to 34.69]), as might be expected in fluid sampled
from closer to the site of estradiol synthesis.
Does the presence of ovarian cysts or dilated rete ovarii 
affect plasma steroid levels?
Estradiol-17β
Plasma estradiol-17β concentrations were compared in
animals with (n = 46) and without (n = 9) ovarian inclu-
sion cysts or dilated rete ovarii. The mean (sd) for the ani-
mals with cysts was 17.4 (9.8) and for those without was
23.3 (11.4). There was not a statistically significant differ-
ence in estradiol between the animals with or without
cysts based on the independent samples t-test (P = 0.124)
or the regression analysis that adjusted for age (P = 0.129).
The unadjusted difference in means for the group with
cysts compared to the group without was -5.8 (95% CI: -
13.1 to 1.6). The adjusted difference of means for the two
groups was -5.7 (95% CI: -13.1 to 1.7). Therefore,
although not statistically significant, there was a tendency
for the animals with cysts to have lower estradiol than the
animals without cysts.
Testosterone
Testosterone concentrations were compared in animals
with (n = 40) and without (n = 10) ovarian inclusion cysts
or dilated rete ovarii. The median (IQR) for the animals
with cysts was 0.28 (0.17–0.47) and for those without was
Representative examples of anti-BrdU immunohistochemistry in the ovaries of IO and BR mice Figure 4
Representative examples of anti-BrdU immunohistochemistry in the ovaries of IO and BR mice. A. BrdU immuno-positive cells 
in the OSE (arrows) adjacent to a follicle (foll) and a corpus luteum in a 9-month IO ovary on the afternoon of estrous. Note 
the labeled cells in the theca and stroma just beneath the OSE. B. Negative control (no primary antibody added) of an adjacent 
section to A. C. Numerous BrdU immuno-positive nuclei (arrows) in the OSE at the base of a recently ovulated follicle (rof) in 
a 6-month BR ovary. D. A single BrdU immuno-positive cell (arrow) is present in this group of three rete ovarii tubules from a 
9-month BR ovary. E. BrdU incorporation in cells present in a hilar cyst (c) in a 12-month BR ovary. F. BrdU incorporation in 
cells, including hobnail cells with clear cytoplasm, lining a cortical cyst in a 12-month IO ovary. Bars = 75 μm; original magnifica-
tion 200 ×.
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0.46 (0.21–0.51). There was not a statistically significant
difference in testosterone between the animals with or
without cysts based on the independent samples t-test (P
= 0.735) or the regression analysis that adjusted for age (P
= 0.460). The unadjusted ratio of geometric means for the
group with cysts compared to the group without was 0.92
(95% CI: 0.58–1.47). The adjusted ratio of geometric
means for the group with cysts compared to the group
without was 0.86 (95% CI: 0.57–1.29).
Androstenedione
Data on androstenedione were available for 47 animals
with cysts and 11 animals without cysts. The median
(IQR) for the animals with cysts was 0.46 (0.32 – 0.66)
BrdU incorporation in the OSE of BR and IO mice, with age (mean +/- one s.d.) Figure 5
BrdU incorporation in the OSE of BR and IO mice, with age (mean +/- one s.d.). Numbers of BrdU-stained nuclei declined with 
age, but significantly higher numbers of stained nuclei were counted in the OSE from IO ovaries compared with BR ovaries (P 
= 0.002). All ovaries were collected on the afternoon of estrus.
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Table 4: Mean (sd) plasma estradiol-17β concentration and median (IQR) plasma testosterone and androstenedione concentrations in 
incessantly ovulating (IO) and breeder (BR) mice killed on the afternoon of estrus, at 6-12 months (m) of age.
Age Treatment n* Estradiol-17β (pg/ml) mean 
(sd)
Testosterone (ng/ml) median 
(IQR)
Androstenedione (ng/ml) median 
(IQR)
6 m IO 19 17.82 (10.61) 0.37 (0.28, 0.64) 0.64 (0.47, 1.41)
BR 15 22.05 (9.35) 0.50 (0.41, 0.80) 0.63 (0.52, 0.84)
9 m IO 12 18.96 (12.79) 0.24 (0.18, 0.26) 0.48 (0.38, 0.67)
BR 15 16.66 (9.58) 0.24 (0.12, 0.48) 0.40 (0.30, 0.53)
12 m IO 16 24.49 (13.60) 0.27 (0.15, 041) 0.43 (0.29, 0.53)
BR 14 22.71 (11.38) 0.19 (0.15, 0.32) 0.32 (0.30, 0.46)
* n = number of animals analyzed per groupReproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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and for those without was 0.50 (0.31–0.69). There was
not a statistically significant difference in androstenedi-
one between the animals with or without cysts based on
the independent samples t-test (P = 0.593) or the regres-
sion analysis that adjusted for age (P = 0.489). The unad-
justed ratio of geometric means for the group with cysts
compared to the group without was 0.91 (95% CI: 0.65–
1.28). The adjusted ratio of geometric means for the group
with cysts compared to the group without was 0.90 (95%
CI: 0.67–1.22).
Discussion
In these experiments, the presence of all ovarian cysts
increased with age rather than total lifetime ovulation
number, as has been previously reported for both mice
[1,2] and women [7]. The majority of the cystic structures
appeared to be dilated rete ovarii tubules. Cortical inclu-
sion cysts, with no connection to the hilus of the ovary,
were extremely rare, as in our previous observations in
animals that were not age-matched [2]. The histology of
the cortical inclusion cyst epithelia, including lack of a
thecal cell layer, low rates of apoptosis, the presence of cil-
iated or flattened cells and E-cadherin immunoreactivity,
suggested these cysts were not follicles that had failed to
ovulate, although this possibility cannot be completely
ruled out.
Although the observed cysts were large and the cyst epi-
thelia showed some dysplasia, no enlarged or abnormal
nuclei or overt epithelial neoplasia were observed. Dila-
tion of the rete ovarii with age has been noted previously
in CD-1 (Swiss Webster) mice [2,19] and appears to be a
feature of this outbred strain, since similar cysts are not
found in 12-month virgin or breeder inbred C57/BL6 or
9-month outbred Quackenbush mice (J. S. Fleming,
unpublished observations). Recent studies by Clark-
Knowles and colleagues showed conditional knockout of
the Brca1 gene in the OSE of FVB mice, led to an increase
in preneoplastic changes in ovarian biology, including
OSE invagination, epithelial cell hyperplasia and small
inclusion cysts, but did not give rise to ovarian cancers, up
to 8 months after inactivation of Brca1 in the OSE [20].
Chodankar et al. also used the Cre-lox system in C57/BL6
mice, driven off a truncated follicle stimulating hormone
receptor promoter, to inactivate Brca1 in granulosa cells
[21]. These conditional knockout mice developed cystic
structures in both ovary and uterus, lined by cells of epi-
thelial morphology, rather than granulosa cells, which
had a normal Brca1  genotype. Two further transgenic
models targeting the activin/Transforming Growth Factor-
β (TGFβ) pathway in the ovary, one expressing a domi-
nant-negative version of the TGF-β transcription factor
Smad2 [22], and the other an inhibin α-subunit transgenic
causing loss of activin activity [23], result in large serous
cysts similar to those observed in this study, with ciliated
and signet ring cyst cells reported. Both these transgenic
mouse strains were developed on a CD-1 background, but
cysts were not present in age-matched wildtype ovaries. It
is notable that none of these models developed epithelial
adenocarcinoma, reiterating that multiple mutational
events are required for transformation of ovarian epithe-
lial cells [24,25].
Low rates of BrdU incorporation were seen in all three epi-
thelial compartments of the ovary, with the lowest rates
observed in the rete ovarii and highest rates in cyst epithe-
lia. This is consistent with previous work showing a higher
rate of PCNA immunoreactivity in cysts compared with
OSE [26] and very low rates of Ki-67 staining in the rete
ovarii [27]. Increased rates of BrdU incorporation in cysts
and the larger size of cysts in older animals, may suggest
the cysts are actively expanding, but it is also possible cyst
cells have higher rates of DNA repair [28,29].
The OSE from older incessantly ovulated ovaries had sig-
nificantly higher rates of BrdU incorporation than OSE
from breeder ovaries, killed at the same time and stage of
the estrous cycle. This result contrasts with our previous
findings of low PCNA staining in the OSE of ovaries from
8-month IO mice [26]. Given the higher number of
PCNA-stained or BrdU-stained cells observed at the base
of ovulation sites ([26] and Figure 4C), the difference
between the IO and BR groups in the current study might
be explained by differences in the number of ovulation
sites per ovary in the two groups at the same age. The total
ovulation number for each animal was estimated, rather
than measured (see Materials and Methods, as well as ref-
erence [1]) so differences in ovulation rate between the
two groups were theoretically possible. However mean lit-
ter size declined only minimally in the breeders with age.
Furthermore, the available follicle pool and thus the ovu-
lation rate might be expected to be lower in older IO mice
compared with breeders and therefore a difference in the
number of ovulations per ovary does not explain the
result observed. The increased BrdU incorporation rate
seen in the OSE of older IO animals may also correlate
with a higher rate of DNA repair in OSE cells involved in
re-epithelialization after many ovulations, although the
kinetics of BrdU incorporation during DNA repair make
this unlikely [28,29]. While the breeder females were not
pregnant at time of death, they had been pregnant consist-
ently since the age of 6-weeks and therefore would have
been exposed to high levels of pregnancy hormones for a
long period of time. Progesterone has been shown to
inhibit OSE proliferation [30] and is thought to be protec-
tive against epithelial ovarian cancer [31,32]. The lower
rates of BrdU incorporation seen in vivo in OSE from older
breeder ovaries therefore supports the inhibitory effects of
progesterone on OSE proliferation observed in vitro. Con-
versely, the increased BrdU incorporation observed in theReproductive Biology and Endocrinology 2007, 5:14 http://www.rbej.com/content/5/1/14
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OSE of OI ovaries may reflect differential gonadotropin
stimulation of the OSE. Repeated ovulatory events, stimu-
lated by more frequent luteinizing hormone (LH) pulses,
might be expected to increase the rate of OSE cell prolifer-
ation in vivo, as has been demonstrated in vitro for murine,
human and ovine OSE cells [33-37] and in vivo after gona-
dotropin-induced superovulation in mice [38,39].
In contrast, BrdU incorporation in cyst epithelial nuclei
did not change significantly with either increasing age or
ovulation number. This observation suggests either cell
cycle regulation or rates of DNA repair differ between the
OSE and cyst epithelial cells. The similarity of BrdU incor-
poration rate in cyst cells from the two groups suggests the
protective role of progesterone does not extend to the
cysts. However the cyst epithelium appears to be capable
of responding to progesterone stimulation, since we (O. L.
Tan and J. S Fleming, unpublished observations) and oth-
ers [40-42] have shown strong expression of progesterone
receptor protein in the nuclei of benign cystadenomas in
both mouse and human. No correlation was demon-
strated between ovarian cyst formation and circulating or
cyst fluid steroid concentrations. Repeated ovulatory
cycles, leading to a high total ovulation number, therefore
do not cause significant changes in plasma androgen or
estradiol-17β concentrations in mice.
E-cadherin protein expression was most pronounced in
the rete ovarii of normal mouse ovaries, using our immu-
nohistochemical conditions. This is in contrast with the
results reported by Woolnough and colleagues [13], who
found no evidence for E-cadherin expression in the
human rete ovarii. E-cadherin is expressed by Mullerian
duct-derived tissues such as oviduct and uterus, however
[43]. The difference in expression pattern may be species-
related, but direct comparison of E-cadherin immuno-
staining in the mouse and human rete ovarii is required to
verify this. Human OSE cells are more mesothelial than
epithelial and express little or no E-cadherin, except occa-
sionally in deep invaginations of OSE [9-11,44]. The peri-
toneal mesothelium also lacks E-cadherin [8]. Acquisition
of E-cadherin immunoreactivity in cuboidal but not flat
cells of human ovarian inclusion cysts, benign cystadeno-
mas and primary low grade adenocarcinoma is well docu-
mented [9,12,45,46]. Loss of E-cadherin
immunoreactivity in high grade tumors is significantly
correlated to increased invasiveness, metastasis and poor
prognosis [5,46]. In this study, apparent dilation of the
rete ovarii was associated with a dramatic reduction in E-
cadherin immunoreactivity in the flat cells lining cysts,
similar to results reported in human ovaries [9]. Given the
size of the mouse rete ovarii system relative to the size of
the mouse ovary, similar dilation of the rete tubules in the
much larger human ovary might not be noticed patholog-
ically. The three cortical inclusion cysts showed variable E-
cadherin immunoreactivity, with one showing little stain-
ing and the two papillary cysts demonstrating strong
staining around cells. The pattern of loss of E-cadherin
immunoreactivity as inclusion cysts form in mouse ova-
ries is consistent with previous observations in human
cystadenomas [9,10,12,44]. However these experiments
demonstrate that E-cadherin alone cannot be used to
determine the cellular origin of the inclusion cysts in
mice, since two papillary cortical inclusion cysts showed
strong immuno-staining, despite not being connected to
the ovarian hilus and therefore potentially to the rete
ovarii. These data also suggest epithelial to mesenchymal
transition is possible in the cortical cyst cells from mouse
ovaries.
Extremely low levels of apoptosis were measured by either
activated-caspase-3 immunohistochemistry or TUNEL
analysis in any of the ovarian epithelial compartments
and the few stained cells observed did not favor any par-
ticular age or treatment group. In mice, basal rates of
apoptosis in the OSE have been reported at around 3%
[47], but a recent study found virtually no apoptosis in the
OSE, even after super-ovulation [38]. In our previous
studies using scanning electron microscopy of the mouse
ovary, incessant ovulation induced higher rates of invagi-
nation and apparent stratification of the OSE [1]. The low
rates of apoptosis observed in the OSE in these experi-
ments, in both BR and IO groups, combined with the
higher rates of BrdU incorporation in the OSE of IO mice,
suggest incessant ovulation affects cell proliferation,
rather than apoptosis, in the OSE.
Conclusion
The results of this age-matched study suggest longer peri-
ods of incessant ovulation do not lead to significant
changes in inclusion cyst formation or steroidogenesis in
CD-1 mice. Inclusion cysts developed with age, rather
than total lifetime ovulation number. Incessant ovulation
has direct effects on the OSE in this mouse strain, increas-
ing cell proliferation and/or DNA damage repair, thus
potentially increasing the chance of invagination and cor-
tical cyst formation, but does not affect circulating steroid
concentrations. The pattern of E-cadherin expression sug-
gests there is heterogeneity in CD-1 mouse ovarian cyst
structure, similar to that seen in human benign serous cys-
tadenomas. We conclude that cortical and hilar cysts can-
not be distinguished by morphology, cell proliferation
rates or E-cadherin immuno-staining characteristics.
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